AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT00162305
- Locations
- 🇺🇸
Local Institution, San Antonio, Texas, United States
Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 17
- Registration Number
- NCT00139074
- Locations
- 🇩🇰
Research Site, Kolding, Denmark
🇩🇰Researcg Site, Svendborg, Denmark
An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 137
- Registration Number
- NCT00135330
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 66
- Registration Number
- NCT00127829
- Locations
- 🇺🇸
Research Site, Palm Springs, California, United States
Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1035
- Registration Number
- NCT00121641
- Locations
- 🇨🇳
Local Institution, Taipei, Taiwan
Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1462
- Registration Number
- NCT00121667
- Locations
- 🇨🇳
Local Institution, Taipei, Taiwan
Seroquel in Bipolar Depression Versus SSRI
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 676
- Registration Number
- NCT00119652
- Locations
- 🇹🇷
Research Site, Manisa, Turkey
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1700
- Registration Number
- NCT00119626
- Locations
- 🇬🇧
Research Site, Glasgow, United Kingdom
Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-06-17
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT00114686
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
- First Posted Date
- 2005-05-30
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00112021
- Locations
- 🇺🇸
Research Site, Olympia, Washington, United States
© Copyright 2024. All Rights Reserved by MedPath